Spero Therapeutics

$16.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.22 (-7.04%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SPRO and other stocks, options, and ETFs commission-free!

About SPRO

Spero Therapeutics, Inc. Common Stock, also called Spero Therapeutics, is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA. The listed name for SPRO is Spero Therapeutics, Inc. Common Stock.

CEO
Ankit A. Mahadevia
Employees
57
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
444.23M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
171.07K
High Today
$17.44
Low Today
$15.50
Open Price
$17.14
Volume
283.12K
52 Week High
$23.64
52 Week Low
$5.25

SPRO Earnings

-$1.32
-$0.88
-$0.44
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Mar 11, After Hours

You May Also Like

GMBTU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure